New York, New York–(Newsfile Corp. – May 25, 2026) – Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. (“Regeneron Pharmaceuticals, Inc.”) (NASDAQ: REGN) concerning potential violations of the federal securities laws.
In March, the Senior Vice President of Investor Relations, Ryan Crowe, told investors management was “hopeful” for the LAG-3 study to show positive differentiators for Fianlimab in combination with Libtayo, such as a low to mid-teens median PFS” and an “opportunity to have a statistically significant, clinically meaningful benefit on OS.”
A little more than two months later, on May 16, 2026, Regeneron disclosed that fianlimab + Libtayo did not meet the trial’s primary endpoint against Keytruda. The upbeat language on potential outcomes offered on March 10, 2026 failed to stress the risk of the trial failure….
PAYROLL & HR CONTROLS (PREVENTING “GHOST” SCHEMES)
Payroll fraud is often the hardest to detect because it “looks” like a normal business expense.
- Segregation of Duties (SoD): The person who adds new employees to the system must not be the same person who approves the monthly pay run.
- Mandatory Vacation Policy: Require all financial and HR staff to take 5–10 consecutive days of leave annually. Fraud often surfaces when the perpetrator isn’t there to “hide” the trail.
- Ghost Employee Audit: Perform a quarterly “Headcount Reconciliation” where managers must physically verify every name on their payroll list exists.
- Self-Pay Blocking: Ensure the payroll software has a hard-coded block preventing administrators from editing their own salary or bank details.